{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:22:12Z","timestamp":1790785332128,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.4065\/mcp.2010.0480","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T18:27:59Z","timestamp":1293733679000},"page":"12-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score"],"prefix":"10.4065","volume":"86","author":[{"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Short-Detweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.4065\/mcp.2010.0480_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archinte.1961.03620030032004","article-title":"\u201cPrimary\u201d systemic amyloidosis and myeloma: discussion of relationship and review of 81 cases","volume":"107","author":"Kyle","year":"1961","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.4065\/mcp.2010.0480_bib2","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"12","key":"10.4065\/mcp.2010.0480_bib3","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4065\/77.12.1278","article-title":"Diagnosing primary amyloidosis","volume":"77","author":"Gertz","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.4065\/mcp.2010.0480_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"1","key":"10.4065\/mcp.2010.0480_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/13506120009146816","article-title":"AL amyloidosis: the last 30 years","volume":"7","author":"Skinner","year":"2000","journal-title":"Amyloid"},{"issue":"10","key":"10.4065\/mcp.2010.0480_bib6","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.4065\/mcp.2010.0480_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","article-title":"Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report","volume":"25","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.4065\/mcp.2010.0480_bib8","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.4065\/mcp.2010.0480_bib9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.4065\/mcp.2010.0480_bib11","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.4065\/mcp.2010.0480_bib12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/mcp.2010.0480_bib13","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2010.0480_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"issue":"4","key":"10.4065\/mcp.2010.0480_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"8","key":"10.4065\/mcp.2010.0480_bib16","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.4065\/mcp.2010.0480_bib19","first-page":"3853","article-title":"A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract 3853]","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.4065\/mcp.2010.0480_bib20","first-page":"428","article-title":"A phase I\/II study of lenalidomide (R) with low dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis [abstract 428]","volume":"114","author":"Kastritis","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"22","key":"10.4065\/mcp.2010.0480_bib22","first-page":"746","article-title":"Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity [abstract 746]","volume":"114","author":"Zonder","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"10.4065\/mcp.2010.0480_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"282","key":"10.4065\/mcp.2010.0480_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"18","key":"10.4065\/mcp.2010.0480_bib26","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.4065\/mcp.2010.0480_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11899-009-0013-6","article-title":"Treatment of immunoglobulin light chain amyloidosis","volume":"4","author":"Gertz","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.4065\/mcp.2010.0480_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.818","article-title":"Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"issue":"17","key":"10.4065\/mcp.2010.0480_bib29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.4065\/mcp.2010.0480_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc072918","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [letter]","volume":"358","author":"Kumar","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/mcp.2010.0480_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.4065\/mcp.2010.0480_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10428190701684518","article-title":"Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis","volume":"49","author":"Gertz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.4065\/mcp.2010.0480_bib33","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.4065\/mcp.2010.0480_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/83.3.297","article-title":"Serum uric acid: novel prognostic factor in primary systemic amyloidosis","volume":"83","author":"Kumar","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"10.4065\/mcp.2010.0480_bib35","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"issue":"8","key":"10.4065\/mcp.2010.0480_bib36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1253\/circj.70.1006","article-title":"Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure","volume":"70","author":"Sakai","year":"2006","journal-title":"Circ J"},{"issue":"3","key":"10.4065\/mcp.2010.0480_bib37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1183\/09031936.99.13368299","article-title":"Hyperuricaemia in patients with right or left heart failure","volume":"13","author":"Hoeper","year":"1999","journal-title":"Eur Respir J"},{"issue":"5","key":"10.4065\/mcp.2010.0480_bib38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/oxfordjournals.eurheartj.a015352","article-title":"Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure","volume":"18","author":"Leyva","year":"1997","journal-title":"Eur Heart J"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611601134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611601134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:38:06Z","timestamp":1706002686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611601134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0025619611601134"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0480","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}